Rebecca Berhanu to Middle Aged
This is a "connection" page, showing publications Rebecca Berhanu has written about Middle Aged.
Connection Strength
0,612
-
Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
Score: 0,088
-
Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia? Int J Tuberc Lung Dis. 2018 08 01; 22(8):358-362.
Score: 0,086
-
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One. 2016; 11(11):e0164974.
Score: 0,077
-
Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury. S Afr Med J. 2015 Apr 07; 105(5):393-6.
Score: 0,069
-
Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa. BMC Public Health. 2019 Jul 22; 19(1):973.
Score: 0,023
-
The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes. 2019 May 31; 17(1):94.
Score: 0,023
-
Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Serv Res. 2018 Dec 17; 18(1):973.
Score: 0,022
-
High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
Score: 0,022
-
Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. J Acquir Immune Defic Syndr. 2018 04 01; 77(4):413-416.
Score: 0,021
-
Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. PLoS One. 2017; 12(7):e0181238.
Score: 0,020
-
Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South Africa. J Int AIDS Soc. 2016 12 22; 19(1):20675.
Score: 0,019
-
Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017 02; 22(2):221-231.
Score: 0,019
-
Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa. AIDS Behav. 2016 11; 20(11):2717-2728.
Score: 0,019
-
Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infect Dis. 2016 Oct 21; 16(1):593.
Score: 0,019
-
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016 09; 21(9):1131-7.
Score: 0,019
-
Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int J Infect Dis. 2015 Oct; 39:89-94.
Score: 0,018
-
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17:19065.
Score: 0,017
-
Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
Score: 0,016
-
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
Score: 0,015